These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8573915)

  • 1. Danger of urokinase as an anticoagulant with left ventricular assist devices.
    Takahama T; Kanai F; Onishi K; Yamazaki Z; Furuse A; Yoshitake T
    ASAIO J; 1995; 41(3):M787-90. PubMed ID: 8573915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ideal anticoagulation for use with a left ventricular assist device.
    Takahama T; Kanai F; Onishi K; Yamazaki Z; Furuse A; Yoshitake T
    ASAIO J; 1995; 41(3):M779-82. PubMed ID: 8573913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations.
    Yamada S; Asakura H
    Int J Hematol; 2021 Jan; 113(1):15-23. PubMed ID: 33175341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of various anticoagulation therapies during use of a left ventricular assist device.
    Takahama T; Kanai F; Hiraishi M; Onishi K; Yamazaki Z; Naruse Y; Furuse A; Yoshitake T
    ASAIO Trans; 1989; 35(3):426-9. PubMed ID: 2597495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation during use of a left ventricular assist device.
    Takahama T; Kanai F; Onishi K
    ASAIO J; 2000; 46(3):354-7. PubMed ID: 10826751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A thromboxane A2 synthetase inhibitor as an anticoagulant for left ventricular assist devices.
    Takahama T; Kanai F; Onishi K
    ASAIO J; 1997; 43(5):M452-6. PubMed ID: 9360083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined administration of protease inhibitor and thromboxane A2 synthetase inhibitor for anticoagulation of a left ventricular assist device.
    Takahama T; Kanai F; Hiraishi M; Onishi K; Yamazaki Z; Naruse Y; Furuse A; Yoshitake T
    ASAIO Trans; 1990; 36(3):M141-4. PubMed ID: 2252644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a protease inhibitor, ulinastatin, on coagulation and fibrinolysis in abdominal surgery.
    Nishiyama T; Yokoyama T; Yamashita K
    J Anesth; 2006; 20(3):179-82. PubMed ID: 16897236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [An experimental study of local fibrinolysis using tissue plasminogen activator and urokinase in a canine common carotid artery thrombus model].
    Kawakami K; Takahashi A; Yoshimoto T
    No To Shinkei; 1990 Feb; 42(2):193-201. PubMed ID: 2113401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of the initial anticoagulant response in tissue-thromboplastin induced intravascular coagulation.
    Tvedskov TF; Vad H; Bendix-Hansen K; Albrechtsen OK; Gram J
    Blood Coagul Fibrinolysis; 1996 Sep; 7(6):595-601. PubMed ID: 8899148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New neonatal problems of blood coagulation and fibrinolysis. I. The change of plasmin inhibitor levels in the newborn infant.
    Suzuki S; Wake N; Yoshiaki K
    J Perinat Med; 1976; 4(4):213-20. PubMed ID: 64604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome.
    Van Geet C; Proesmans W; Arnout J; Vermylen J; Declerck PJ
    Kidney Int; 1998 Oct; 54(4):1324-30. PubMed ID: 9767551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel chimaeric derivative of saruplase, rscu-PA-40 kDA/Hir, binds to thrombin and exerts thrombus-specific fibrinolysis in arterial and venous thrombosis in dogs.
    Schneider J; Hauser R; Hennies HH; Korioth J; Steffens G; Wnendt S
    Thromb Haemost; 1997 Mar; 77(3):535-9. PubMed ID: 9066007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concepts of clot lysis.
    Francis CW; Marder VJ
    Annu Rev Med; 1986; 37():187-204. PubMed ID: 2939790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].
    Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K
    Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coagulation and fibrinolysis study after local thrombolysis of a cerebral artery with urokinase.
    Oyama H; Iwakoshi T; Niwa M; Kida Y; Tanaka T; Kitamura R; Maezawa S; Kobayashi T
    Neurol Med Chir (Tokyo); 1996 May; 36(5):300-4. PubMed ID: 8710052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
    Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aqueous extract from Brownea grandiceps flowers with effect on coagulation and fibrinolytic system.
    Pereira B; Brazón J
    J Ethnopharmacol; 2015 Feb; 160():6-13. PubMed ID: 25460592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
    Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
    Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.